Neuroscience Antibodies & Assays Market Size by Top Companies, Regions, Types and Application, End Users and Forecast to 2027 – Bulletin Line

August 13, 2020 medical

New Jersey, United States,- Verified Market Researchhas recently published an extensive report on the Neuroscience Antibodies & Assays Market to its ever-expanding research database. The report provides an in-depth analysis of the market size, growth, and share of the Neuroscience Antibodies & Assays Market and the leading companies associated with it. The report also discusses technologies, product developments, key trends, market drivers and restraints, challenges, and opportunities. It provides an accurate forecast until 2027. The research report is examined and validated by industry professionals and experts.

The report also explores the impact of the COVID-19 pandemic on the segments of the Neuroscience Antibodies & Assays market and its global scenario. The report analyzes the changing dynamics of the market owing to the pandemic and subsequent regulatory policies and social restrictions. The report also analyses the present and future impact of the pandemic and provides an insight into the post-COVID-19 scenario of the market.

Global Neuroscience Antibodies & Assays Market was valued at USD 2.42 Billion in 2018 and is projected to reach USD 5.14 Billion by 2026, growing at a CAGR of 9.7% from 2019 to 2026.

The report further studies potential alliances such as mergers, acquisitions, joint ventures, product launches, collaborations, and partnerships of the key players and new entrants. The report also studies any development in products, R&D advancements, manufacturing updates, and product research undertaken by the companies.

Leading Key players of Neuroscience Antibodies & Assays Market are:

Competitive Landscape of the Neuroscience Antibodies & Assays Market:

The market for the Neuroscience Antibodies & Assays industry is extremely competitive, with several major players and small scale industries. Adoption of advanced technology and development in production are expected to play a vital role in the growth of the industry. The report also covers their mergers and acquisitions, collaborations, joint ventures, partnerships, product launches, and agreements undertaken in order to gain a substantial market size and a global position.

Global Neuroscience Antibodies & Assays Market, By Product

Consumables Instruments

Global Neuroscience Antibodies & Assays Market, By Technology

Clinical Chemistry Immunoassays/Immunochemistry Molecular Diagnostics Other Technologies

Global Neuroscience Antibodies & Assays Market, By Application

Drug Discovery & Development Research in Vitro Diagnostics

Global Neuroscience Antibodies & Assays Market, By End-User

Hospitals & Diagnostics Centers Pharmaceutical & Biotechnology Companies Academic & Research Institutes

Regional Analysis of Neuroscience Antibodies & Assays Market:

A brief overview of the regional landscape:

From a geographical perspective, the Neuroscience Antibodies & Assays Market is partitioned into

North Americao U.S.o Canadao MexicoEuropeo Germanyo UKo Franceo Rest of EuropeAsia Pacifico Chinao Japano Indiao Rest of Asia PacificRest of the World

Key coverage of the report:

Other important inclusions in Neuroscience Antibodies & Assays Market:

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll-Free: +1 (800)-7821768

Email: [emailprotected]

View original post here:
Neuroscience Antibodies & Assays Market Size by Top Companies, Regions, Types and Application, End Users and Forecast to 2027 - Bulletin Line

Immunology

Saag named division director of Clinical Immunology and Rheumatology – UAB News

August 12, 2020 medical

A long time UAB rheumatologist has been named director of division in the UAB School of Medicine.

Kenneth G. Saag, M.D., MScKenneth G. Saag, M.D., MSc, has been named director of the Division of Clinical Immunology and Rheumatology at the University of Alabama at Birmingham. He is the Jane Knight Lowe Professor and also serves as vice chair of Outcomes and Effectiveness Research in UABs Department of Medicine.

Saag has been a practicing physician with UAB Medicine and researcher in the UAB School of Medicine for 23 years, with particular expertise in osteoporosis, gout, and outcomes research.

Im humbled to serve our division as director and to continue to build upon the reputation of patient-centered care, academic prowess and national leadership in the field that UAB Rheumatology is known for, Saag said. I have ambitious plans to grow our faculty and fellowship program, expand our clinical services, and enhance both clinical and fundamental scientific research in rheumatology and immunology. Im excited for what is to come for our faculty and patients alike.

He succeeds former division director S. Louis Bridges Jr., M.D., Ph.D., effective July 1, 2020.

Saag will begin serving as president-elect of the American College of Rheumatology this fall and he is past-president of the National Osteoporosis Foundation. He has served UAB as director of the Center for Outcomes, Effectiveness Research and Education (COERE) since 2009, and directs the Center of Research Translation (CoRT) in Gout and Hyperuricemia, a program supported by the NIH for nearly a decade. He also serves as Vice Chair for Outcomes and Effectiveness Research in the Department.

UABs Rheumatology program was just ranked 10 in the nation by U.S. News and World Report.

Immunology

ImmunoScape Targets Immunology Breakthroughs for COVID-19 and Oncology with $11M in Global Financing Led by Anzu Partners and UTEC – BioSpace

August 12, 2020 medical

SINGAPORE and SAN DIEGO, Aug. 12, 2020 /PRNewswire/ --immunoSCAPE (www.ImmunoScape.com), a biotech firm enabling unprecedented insights into the human immune system, today announced that it has raised USD $11 million (SGD $14.8 million) in a global equity financing round. US-based venture firm Anzu Partners led the round, joined by University of Tokyo Edge Capital (UTEC) in Japan, and NPR Holdings in Indonesia.

ImmunoScape's immune profiling platform, which provides deep insights into the T-cells of the human immune system, is already intensely engaged in COVID-19 related programs on three continents.

"There is an urgent need to understand how the T-cell immune response contributes to COVID-19 immunity and can be leveraged for vaccine design," said ImmunoScape co-founder and Chief Operating Officer Dr. Alessandra Nardin. "In global collaborations with Massachusetts General Hospital, University of Parma (Italy), and Duke-NUS, we are evaluating COVID-19 patients and recovered individuals. We are building a large data set on human T-cell response to COVID-19, in an effort to develop new therapies and better vaccines with our partners."

ImmunoScape also has established collaborations with several vaccine development companies, including the San Diego-based Arcturus which is running clinical trials in Singapore.

"As a Singapore-based firm supported by the Agency for Science Technology and Research (A*STAR), our team has deep experience assessing T-cell immune response to dengue, hepatitis B, and other viruses. It was clear that we must provide deep support to COVID-19 vaccine development in this global crisis," said ImmunoScape co-founder and CEO Choon Peng Ng, formerly a senior executive at A*STAR.

The company also aspires to continue its core mission of enabling advanced immunotherapies for cancer, an area where its scientific track record is very strong. "In 2019 we co-authored a paper together with collaborators at Genentech illustrating the role of our technology in evaluating checkpoint blockade immunotherapies," said Dr. Nardin. "The interest in those insights attracted global attention and encouraged us to seek financing to expand further into the US market."

"To deliver on the promise of individualized medicine for cancer, the biopharma industry desperately needs more insight into every patient's unique immune system. ImmunoScape can deliver this, and we are delighted to support them," said David Michael, Managing Partner of Anzu Partners.

ImmunoScape's technology can guide the development of immunotherapies, as the company has shown in major scientific journals," said Dr. Naonori Kurokawa, Partner of UTEC. "Now they are bringing these insights and capabilities to major biopharma clients globally."

ImmunoScape's technology was based on work begun at Stanford University, and continued at A*STAR of Singapore, where the company was established in 2017. ImmunoScape has received support from A*STAR and its commercialization arm A*ccelerate, as well as Enterprise Singapore. Technical founder Dr. Evan Newell, PhD, previously an A*STAR Science Fellow, is now based at Seattle's Fred Hutchinson Cancer Research Center.

For more information, please visit: https://ImmunoScape.com

About ImmunoScapeImmunoScape specializes in deep profiling of immune cells and identification of antigen specific T cells, based on the high dimensional mass spectrometry methods developed by Dr. Evan Newell, the company's co-founder. ImmunoScape enables pharmaceutical and biotechnologies companies to gain valuable insights from clinical trial patient data and to develop more effective immunotherapies. For more information, please visit https://ImmunoScape.com.

About ANZU PartnersAnzu Partners is an investment firm that funds breakthrough industrial and life sciences technologies. Anzu teams with entrepreneurs to develop and commercialize technological innovations by providing capital and deep expertise in business development, market positioning, global connectivity, and operations. For more information, please visit https://anzupartners.com. On Twitter: @anzupartners.

About UTECUTEC is a seed/early stage technology focused venture capital firm associated with academic institutes such as The University of Tokyo. UTEC supports the creation and growth of start-ups that vigorously foster business globally through the use of superior science and technology, collaborating with universities, research institutes and investment partners in and out of Japan. For more information, please visit https://www.ut-ec.co.jp/english/.

CONTACTRob Haralson for ImmunoScape+12026746679, rhh@anzupartners.cominfo@immunoscape.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/immunoscape-targets-immunology-breakthroughs-for-covid-19-and-oncology-with-11m-in-global-financing-led-by-anzu-partners-and-utec-301110607.html

SOURCE ImmunoScape

Immunology

Neutrophils key to mounting effective immune response when receiving pneumonia vaccine, preclinical study shows – UB Now: News and views for UB…

August 12, 2020 medical

UB scientists exploring the nature of immunity after vaccination against Streptococcus pneumoniae, which causes pneumonia in people, have discovered that a specific type of white blood cell called neutrophils plays a more critical role than was previously known.

The research is especially relevant for the elderly because immunity declines with age.

Researchers at the Jacobs School of Medicine and Biomedical Sciences at UB have found that in order to generate a protective response when vaccinated against Streptococcus pneumoniae, an individual must have a sufficient level of neutrophils.

The preclinical study is important because it is the first to use Prevnar-13, one of two pneumonia vaccines on the market, instead of a model antigen to study the nature of the immune response triggered by the vaccine.

The idea behind our research is ultimately to make a better pneumonia vaccine, says Elsa Bou Ghanem, assistant professor of microbiology and immunology in the Jacobs School and senior corresponding author on the paper, published in May in the Journal of Infectious Diseases.

While B cells are a key factor in the immune response because they produce antibodies that fight viruses and pathogens, Bou Ghanem says the new findings about neutrophils could be relevant to potential improvements in developing vaccines against S. pneumoniae.

Now we have to think about the other immune cells in the mix as well, she says. Now we understand that its a little more complicated.

Bou Ghanem describes neutrophils as the first defenders, noting that whenever any foreign object appears in the lungs, neutrophils are the first infection-fighting cells to appear.

That fact has long been known about neutrophils, also known as polymorphonuclear leukocytes (PMNs). They play key roles in the bodys rapid response to bacterial infection, known as the innate response.

But the UB researchers found that they also play a role in generating the adaptive response, the immune systems slower, more customized response to a specific infection.

We have learned now that neutrophils orchestrate the whole immune response, both innate and adaptive, says Essi Tchalla, first author on the paper and a doctoral student in the Department of Microbiology and Immunology in the Jacobs School.

They made the discovery while studying how two groups of mice responded after being vaccinated with the polysaccharide conjugate vaccine: One group was normal and one group had had its neutrophils significantly depleted.

When exposed to S. pneumoniae a month after vaccination, all of the mice with normal neutrophil levels were able to mount a strong immune response and all of them survived, with only 12.5% of them showing any symptoms.

But in the group that had been depleted of neutrophils at the time of vaccination, nearly 80% became severely ill and more than half of the mice did not survive. These mice exhibited between 10 and 100 times more bacteria in their lungs than was seen in the normal controls.

The researchers report it was the lack of neutrophils at the time when mice were vaccinated, not at the time of exposure to the bacteria, that caused them to suffer the worst outcomes. The neutrophils were required for the production of protective antibodies against S. pneumoniae following vaccination.

Now we want to figure out what is the contribution of neutrophils in regulating this vaccine response, Tchalla says.

She explains the team is looking at interferon gamma, which is involved in the innate immune response, and the possibility that neutrophils can produce interferon gamma, which in turn helps B cells to produce better antibodies against pathogens.

The long-range goal for Bou Ghanem and Tchalla is to investigate how the reduction in the efficacy of neutrophils in the elderly affects their ability to mount an immune response to S. pneumoniae when vaccinated.

One of their projects, currently on hold because of the pandemic, involves studying neutrophils provided by donors recruited through UBs Clinical and Translational Research Institute, a collaboration with Sanjay Sethi, professor and chief of the Division of Pulmonary, Critical Care and Sleep Medicine in the Jacobs School.

The findings may also be relevant to understanding the ability of elderly patients to generate an adequate immune response when vaccinated against other pathogens, including COVID-19, the UB researchers say.

The research was funded by the National Institutes of Health. Bou Ghanem has received additional NIH funding to study the factors that make the elderly susceptible to S. pneumoniae, and how to make vaccines more effective in elderly populations, in collaboration with Blaine Pfeifer, professor in the Department of Chemical and Biological Engineering, School of Engineering and Applied Sciences.

In addition to Bou Ghanem and Tchalla, co-authors are Manmeet Bhalla, postdoctoral associate in Bou Ghanems lab, and Elizabeth A. Wohlfert, assistant professor in the Department of Microbiology and Immunology.

Read this article:
Neutrophils key to mounting effective immune response when receiving pneumonia vaccine, preclinical study shows - UB Now: News and views for UB...

Immunology

Coronavirus: does the common cold protect you from COVID? – The Conversation UK

August 12, 2020 medical

An article in Science recently generated a lot of interest by providing a possible explanation of why COVID-19 can be deadly to some yet go virtually unnoticed in others.

Scientists at La Jolla Institute for Immunology in California showed that infection with common cold coronaviruses can generate an immune response that resembles key pieces of the immune response generated by SARS-CoV-2 the virus that causes COVID-19. This raises the possibility that previous infection with one of the milder coronaviruses could make COVID-19 less severe. But how likely is this? And how does this relate to what we already know about coronaviruses?

A few weeks ago, a different article sat at the centre of the SARS-CoV-2 immunity debate. This one showed that the antibody response to SARS-CoV-2 may decline over time.

The findings raised concern that SARS-CoV-2 could infect a person many times and that a vaccine might not generate lasting protection. But the article focused on just one arm of the immune response, the B cells, which produce antibodies that help to clear an infection.

T cells are also key to the immune response against viruses. They play a variety of roles, among them helping B cells to mature into disease-fighting machines. The article by Jose Mateus and colleagues at La Jolla Institute for Immunology is important because it shows that people keep T cells from the milder coronaviruses long enough to potentially interact with a new challenge by SARS-CoV-2 and that those T cells might even recognise SARS-CoV-2 and help to clear the infection.

For epidemiologists, the evidence of waning immunity and cross-immunity didnt come as a surprise. A study from 1990 showed that soldiers infected with one of the milder coronaviruses didnt retain immunity for much longer than a year. Also, the boom-bust cycle that the milder coronaviruses undergo from year to year can be explained by a mix of waning immunity and cross-immunity.

The milder coronaviruses can generate similar antibodies to the ones that are generated by the coronaviruses that cause Sars and Mers. These antibodies are so similar that they nearly tricked a British Columbia care facility into thinking they had an outbreak of Sars after the Sars epidemic had been declared over. In fact, the outbreak was caused by OC43, one of the coronaviruses that causes the common cold.

Nevertheless, infections that generate structurally similar antibodies dont necessarily provide cross-protection in a medically meaningful way.

Evidence for cross-protection between all but the most closely related coronaviruses is scant.

It is difficult to say whether the milder coronaviruses protect against SARS-CoV-2 partly because we have done so little surveillance on them. Ideally, we would be able to look at historical data to identify which communities experienced major outbreaks of each milder coronavirus strain over the past few years and then see if there is a link with less severe COVID-19 cases.

Challenge studies, in which a person is intentionally infected with a milder coronavirus strain and then exposed to SARS-CoV-2, could also address the question but are dangerous and ethically fraught. For now, all we can say is that the possibility that the common coronaviruses might protect against SARS-CoV-2 remains just that a possibility. Indeed, Mateus and colleagues describe this theory as highly speculative.

View original post here:
Coronavirus: does the common cold protect you from COVID? - The Conversation UK

Immunology

Tevogen Bio Announces Partnership With Preeminent Scientist Professor Neal Flomenberg, MD, to Investigate Proprietary T-Cell Therapy for Treatment of…

August 12, 2020 medical

METUCHEN, N.J., Aug. 10, 2020 /PRNewswire/ --Tevogen Bio announces a joint partnership with renowned bone-marrow transplant expertNeal Flomenberg, M.D., Professor and Chair of the Department of Medical Oncology at Thomas Jefferson University, with the intent to evaluate Tevogen' s proprietary antigen-specific T cell technology as a potential treatment for COVID-19 and influenza-A patients.

This collaboration aims to harness Tevogen's proprietary immunotherapy platform and Dr. Flomenberg's expertise and research prowess to investigate potential treatments for viral infections.

Dr. Flomenberg has been at the forefront of immunogenetics and immunology for more than four decades. "Tevogen's technology resonated with me as there have been several groups who have used T cells to treat patients after bone-marrow transplants. The idea of utilizing T cell therapies to potentially treat COVID-19 and other viruses is truly remarkable," Flomenberg said. "I'm enthusiastic about moving forward with an investigation of Tevogen's technologies."

Tevogen CEO Ryan Saadi, M.D., M.P.H., is leading the new biotech's efforts. "Our work has been to pioneer T cell therapies that can be abundantly and efficiently reproduced to develop an affordable and scalable cellular treatment for the biggest global health threats, including COVID-19, influenza, and a variety of cancers. We are very excited about Dr. Flomenberg's contribution to our efforts and hope to initiate our investigational study soon."

In addition to developing its potential therapies, Tevogen is committed to organizational and manufacturing efficiency. This should allow it to engage in affordable innovation to the benefit of all patients.

About Tevogen Bio

Tevogen Bio was formed after decades of research by its contributors to concentrate and leverage their expertise, spanning multiple sectors of the health care industry, to help address some of the most common and deadly illnesses known today. The company's mission is to provide curative and preventative treatments that are affordable and scalablein order to positively impact global public health.

About Dr. Neal Flomenberg

Dr. Neal Flomenberg is the Chairman of Medical Oncology at Jefferson University in Philadelphia and also heads the Hematologic Malignancies, Blood and Marrow Transplantation (BMT) Program. Throughout his more than four decades of practice, he has maintained a longstanding interest in the immunogenetics and immunology of stem cell transplantation, with the goal of making transplantation safer and more widely available. Dr. Flomenberg developed an approach to bone-marrow transplants that uses half-matched relatives as donors, a breakthrough that assures that the majority of blood and bone-marrow cancer patients can benefit from this potentially curative treatment.

Media Contacts:

Mark Irion[emailprotected]

Katelyn Petroka [emailprotected]

SOURCE Tevogen Bio

Link:
Tevogen Bio Announces Partnership With Preeminent Scientist Professor Neal Flomenberg, MD, to Investigate Proprietary T-Cell Therapy for Treatment of...

Immunology

Why are some people protected from Covid-19 without having contracted the disease? – EL PAS in English

August 12, 2020 medical

After months of uncertainty and grim headlines, some scientists are hesitantly recognizing what could be good news. During the first weeks of the Covid-19 pandemic, it was estimated that around 60% of the population would need to be exposed to the coronavirus to achieve herd immunity, which occurs when a high percentage of the community is immune to a disease.

A large-scale antibody study in Spain found that around 5% of the population had contracted the coronavirus, with significant differences between the regions in the Soria province, the figure was more than 14%, compared to 1.2% in Cdiz. The hope of achieving herd immunity seemed like a long shot. But as time passed, a growing amount of research began to suggest that more people are protected against the coronavirus, or at least its most serious versions, than the antibody studies indicated. Experts, however, do not want this news to be used as an excuse for the relaxation of coronavirus safety measures.

When there is an infection from a virus of the same family there could be a cross-reaction and the immune system could develop antibodies similar to the ones that neutralized the other virus

We have been living with coronaviruses for a very long time. Most of them cause minor respiratory problems [like the common cold], while others are more serious, like SARS and MERS, explains Juan Pablo Horcajada, the head of infectious diseases at the Mar Hospital in Barcelona. Four viruses in the coronavirus family cause around 25% of colds, and it is well known that when there is an infection from a virus of the same family there could be a cross-reaction and the immune system could develop antibodies similar to the ones that neutralized the other virus, he explains. What we dont know yet is if these antibodies can offer protection and if so, to what extent.

A study recently published in the journal Science estimated that at least 20% or perhaps up to 50% of people who have never contracted SARS-CoV-2 have some kind of cellular protection against the disease. It is likely this has been generated by previous contact with one of the coronaviruses that cause colds. The research, however, has been done on cell samples and the hypothesis still needs to be tested out in real situations and on real people. For now, the authors of the study, researchers from La Jolla Institute for Immunology in the United States, acknowledge that it is very speculative to link the better prognosis of some Covid-19 patients with their previous exposure to the coronaviruses that cause the common cold.

Similar research from other groups has found the presence of protective T cells, the white blood cells that destroy infected cells in the body, in between 40% and 81% of samples. This would explain the behavior of the pandemic in the last few weeks, says Manel Juan, the head of immunology at Clnic hospital in Barcelona. Although there is concern about the rise in cases, we are not seeing a repeat of the situation in March [when there were hundreds of daily deaths and hospitalizations] and this could be because a greater percentage of people are protected than is reflected in the antibody tests.

According to one study, up to 50% of people who have never contracted SARS-CoV-2 have some kind of cellular protection against the disease

Luisa Villar, the head of immunology at the Ramn y Cajal hospital in Madrid, says that more infections would have been expected, given that only 11% of people in the Madrid region have had the coronavirus, according to the serological study.

According to Villar, the response of T cells, developed by contact with similar viruses or a persons very immune system, could also explain the heterogeneous impact of the disease. In young people, T cells are more active, but this response starts to decline from the age of 70, she says. Thats why young people may have a minor case or even be asymptomatic, while seniors have much more serious symptoms.

One of the reasons why coronaviruses can cause colds is that they share a viral spicule protein that is used to colonize host cells. The laboratories working on a vaccine for Covid-19 see this spicule as the key to developing an immunological response.

While the research may explain why young people have less serious cases of Covid-19, it does not explain the gap in the contagion rates between Spains 17 regions. I would have thought that there would have been more protection in the north of Spain, because you would think there would be more colds there, but thats not what we are seeing, says Juan.

In young people, T cells are more active, but this response starts to decline from the age of 70

Jess Rodrguez Bao, the head of infectious disease at the Virgen Macarena hospital in Seville, also backs the hypothesis that people have more immunity to Covid-19 because they have been in contact with similar diseases, but says there still needs to be epidemiological confirmation of the data. Its a similar situation with the flu. There is a certain degree of immunity after contracting a virus like the flu, he explains, adding that given the virus has led to a global pandemic its unlikely that the immunity is widespread.

A better understanding of the immunity of a population could shed light on the mysteries that remain about why Covid-19 affects people so differently. But measuring real immunity, beyond the presence of antibodies, requires tests that are expensive and difficult to carry out. In Barcelona, Manel Juan is leading a European project to develop an easier and faster test for determining who has immunity from T cells. This information could be used to help find out who is protected and to what extent, and also help design new vaccines, which help the body to generate a more efficient reaction against the coronavirus. For the moment, however, the good news that people who have never had contact with the virus can be protected needs confirmation via research.

English version by Melissa Kitson.

Immunology

Neutrophils are key to mounting an effective immune response when receiving a pneumonia vaccine – UB News Center

August 12, 2020 medical

BUFFALO, N.Y. University at Buffalo scientists exploring the nature of immunity after vaccination against Streptococcus pneumoniae, which causes pneumonia in people, have discovered that a specific type of white blood cell called neutrophils plays a more critical role than was previously known.

The research is especially relevant for the elderly because immunity declines with age.

Better vaccines

The idea behind our research is ultimately to make a better pneumonia vaccine, said Elsa Bou Ghanem, PhD, assistant professor of microbiology and immunology in the Jacobs School and senior corresponding author on the paper, published in the Journal of Infectious Diseases in May.

While B cells are a key factor in the immune response because they produce antibodies that fight viruses and pathogens, Bou Ghanem said the new findings about neutrophils could be relevant to potential improvements in developing vaccines against S. pneumoniae.

Now we have to think about the other immune cells in the mix as well, she said. Now we understand that its a little more complicated.

Bou Ghanem described neutrophils as the first defenders, noting that whenever any foreign object appears in the lungs, neutrophils are the first infection-fighting cells to appear.

But the UB researchers found that they also play a role in generating the adaptive response, the immune systems slower, more customized response to a specific infection.

Orchestrating the whole immune response

We have learned now that neutrophils orchestrate the whole immune response, both innate and adaptive, said Essi Tchalla, first author on the paper and a doctoral student in the Department of Microbiology and Immunology in the Jacobs School.

Now we want to figure out what is the contribution of neutrophils in regulating this vaccine response, said Tchalla.

She said the team is looking at interferon gamma, which is involved in the innate immune response, and the possibility that neutrophils can produce interferon gamma, which in turn helps B cells to produce better antibodies against pathogens.

One of their projects, currently on hold because of the pandemic, involves studying neutrophils provided by donors recruited through UBs Clinical and Translational Research Institute, a collaboration with Sanjay Sethi, MD, professor and chief of the Division of Pulmonary, Critical Care and Sleep Medicine in the Jacobs School.

The research was funded by the National Institutes of Health. Bou Ghanem has received additional NIH funding to study the factors that make the elderly susceptible to S. pneumoniae, and how to make vaccines more effective in elderly populations, in collaboration with Blaine Pfeifer, PhD, professor in the Department of Chemical and Biological Engineering in the UB School of Engineering and Applied Sciences.

In addition to Bou Ghanem and Tchalla, co-authors are Manmeet Bhalla, PhD, postdoctoral associate in Bou Ghanems lab, and Elizabeth A. Wohlfert, PhD, assistant professor in the Department of Microbiology and Immunology in the Jacobs School.

Originally posted here:
Neutrophils are key to mounting an effective immune response when receiving a pneumonia vaccine - UB News Center

Immunology

AZTherapies Announces the Appointment of Drs. Robert Malenka, Adam Boxer, Vijay Kuchroo and Megan Levings, to Scientific Advisory Board – Stockhouse

August 12, 2020 medical

BOSTON, Aug. 11, 2020 (GLOBE NEWSWIRE) -- AZTherapies, Inc., a biopharmaceutical company in advanced clinical trials to treat neuroinflammatory diseases, today announced the expansion of its Scientific Advisory Board, appointing esteemed neuroscientist Robert Malenka, M.D., Ph.D., as well as experts in the development of neuroimmunology and T-cell therapeutics, Adam Boxer, M.D., Ph.D., Vijay Kuchroo, D.V.M., Ph.D., and Megan Levings, Ph.D., who have joined the AZTherapies SAB following the company’s acquisition of Smith Therapeutics in October 2019.

We are very pleased to welcome these neuro-immunology leaders to our Scientific Advisory Board, as we are all committed to advancing efforts to slow down or halt the progression of neurodegenerative diseases by targeting neuroinflammation as the main cause of progressive neural damage, and declining cognition and function,” said David R. Elmaleh, Ph.D., AZTherapies’ Founder, CEO, and Chairman. Each of our new board members brings unique expertise relevant to our pipeline whether it be our Phase 3 program in early Alzheimer’s disease, our progressing candidate for the treatment of ALS and post-ischemic stroke cognitive impairment, or our novel biologic approach using specifically engineered immunosuppressive CAR-T regulatory (Treg) cells to treat neurodegenerative disease and I look forward to working together to achieve our common goals.”

Philip Ashton-Rickardt, Ph.D., Senior Vice President, Immunology at AZTherapies also commented on the appointments: I am thrilled that the SAB members from Smith have agreed to stay on to support our efforts in the development of CAR-Tregs to restore a healthy balance of inflammatory and regulatory cells in the brain. Since last fall, we have continued to advance this innovative program through pre-clinical development, and now anticipate initial in vitro and in vivo proof of concept across several models of neurodegenerative disease later this year.”

Dr. Malenka is Deputy Director of the Wu Tsai Neurosciences Institute and Associate Chair of the Department of Psychiatry and Behavioral Science at Stanford University, while also serving as the Pritzker Professor of Psychiatry & Behavioral Sciences. Recognized as a world leader in the field of synapse biology, his work has resulted in more than 250 scientific publications. Dr. Malenka is an elected member of both the National Academy of Sciences and the National Academy of Medicine as well as the American Academy of Arts and Sciences. He received a B.A., summa cum laude, from Harvard College and an M.D. and a Ph.D. in neuroscience from Stanford University School of Medicine.

Dr. Boxer is Endowed Professor in Memory and Aging in the Department of Neurology at the University of California, San Francisco (UCSF) and directs UCSF’s Neurosciences Clinical Research Unit and the Alzheimer’s Disease and Frontotemporal Degeneration (FTD) Clinical Trials Program at the UCSF Memory and Aging Center. Dr. Boxer’s research is focused on developing new treatments and biomarkers for neurodegenerative diseases. He is the principal investigator of the Advancing Research and Treatment for Frontotemporal Lobar Degeneration Clinical Research Consortium, while also leading the FTD Treatment Study Group, which is looking to speed the development of new therapies for FTD. The author of more than 150 scientific publications, Dr. Boxer received his medical and doctorate degrees at New York University Medical Center.

Dr. Kuchroo is the Samuel L. Wasserstrom professor of neurology at Harvard Medical School, and a senior scientist at Brigham and Women’s Hospital. He is also a member of the Broad Institute, and a participant in a Klarman Cell Observatory project that focuses on T cell differentiation. He is the founding director of the Evergrande Center for Immunologic Diseases at Harvard Medical School and Brigham and Women’s Hospital. Dr. Kuchroo obtained his degree in Veterinary Medicine from the College of Veterinary Medicine, Hisar, India, and subsequently specialized in pathology at the University of Queensland, Brisbane Australia, where he obtained a Ph.D. He is the recipient of the Fred Z. Eager Research Prize, the Javits Neuroscience Award by the NIH, the Ranbaxy Prize in Medical Research, the Nobel Laureate Peter Doherty Lecture/Prize, and was named Distinguished Eberly Lecturer.

Dr. Levings is Professor, Department of Surgery and School of Biomedical Engineering, Faculty of Medicine at the University of British Columbia, Investigator at BC Children’s Hospital Research Institute, Lead, Childhood Diseases Research Theme, and an Associate Member of the Department of Microbiology and Immunology. She is internationally recognized in the field of human immunology and currently chairs the Federation of Clinical Immunology Societies Centers' of Excellence and is a member of the NIH-funded Immune Tolerance Network steering committee. Her research focuses on the use of T regulatory cells to replace conventional immunosuppression in the context of transplantation and autoimmunity. Dr. Levings received her BSc in biology from Simon Fraser University and her Ph.D. in genetics at the University of British Columbia.

About AZTherapies AZTherapies is an advanced clinical-stage biopharmaceutical company developing novel small molecules and biologic therapies that aim to fundamentally change neurodegenerative disease progression, extending normal cognition and function and improving quality of life in the aging population. Our lead candidate, ALZT-OP1, is built on a multi-modal approach that recognizes neuroinflammation as a root cause of serious neurodegeneration and seeks to stop or slow the progression of disease; the ALZT-OP1 Phase 3 COGNITE trial in early Alzheimer’s disease is fully enrolled, with trial completion expected in late 2020 and results in the first quarter of 2021. Following our lead program, we are advancing candidates for the treatment of amyotrophic lateral sclerosis (ALS), post-ischemic stroke cognitive impairment, and are pursuing an innovative CAR-Treg program that could have broad application across a spectrum of neurodegenerative diseases. AZTherapies is a private company headquartered in Boston, Massachusetts. To learn more, please visit http://www.aztherapies.com.

Media Contact: Jennifer LaVin jlavin@aztherapies.com

Investor Contact: Brian Bartlett Chief Financial & Accounting Officer brian.bartlett@aztherapies.com

Read the original:
AZTherapies Announces the Appointment of Drs. Robert Malenka, Adam Boxer, Vijay Kuchroo and Megan Levings, to Scientific Advisory Board - Stockhouse

Genetics

Insights on the Global Animal Genetics Market 2020-2024 | COVID-19 Analysis, Drivers, Restraints, Opportunities and Threats | Technavio – Business…

August 12, 2020 medical

LONDON--(BUSINESS WIRE)--Technavio has been monitoring the animal genetics market and it is poised to grow by USD 1.79 billion during 2020-2024, progressing at a CAGR of 7% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Please Request Free Sample Report on COVID-19 Impact

Frequently Asked Questions-

The market is concentrated, and the degree of concentration will accelerate during the forecast period. Animal Genetics Inc., AquaGen AS, Aviagen Group, Coperatie Koninklijke CRV u.a., Genetic Veterinary Sciences Inc., Genus Plc, Hendrix Genetics BV, Neogen Corp., Topigs Norsvin, and Zoetis Inc. are some of the major market participants. To make most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

Animal Genetics Market 2020-2024: Segmentation

Animal Genetics Market is segmented as below:

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR40040

Animal Genetics Market 2020-2024: Scope

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. Our animal genetics market report covers the following areas:

This study identifies the increase in consumption of animal-derived food products as one of the prime reasons driving the animal genetics market growth during the next few years.

Animal Genetics Market 2020-2024: Vendor Analysis

We provide a detailed analysis of vendors operating in the animal genetics market, including some of the vendors such as Animal Genetics Inc., AquaGen AS, Aviagen Group, Coperatie Koninklijke CRV u.a., Genetic Veterinary Sciences Inc., Genus Plc, Hendrix Genetics BV, Neogen Corp., Topigs Norsvin, and Zoetis Inc. Backed with competitive intelligence and benchmarking, our research reports on the animal genetics market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.

Register for a free trial today and gain instant access to 17,000+ market research reports. Technavio's SUBSCRIPTION platform

Animal Genetics Market 2020-2024: Key Highlights

Table of Contents:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

PART 04: MARKET SIZING

PART 05: FIVE FORCES ANALYSIS

PART 06: MARKET SEGMENTATION BY SOLUTION

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

PART 13: VENDOR ANALYSIS

PART 14: APPENDIX

PART 15: EXPLORE TECHNAVIO

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

More:
Insights on the Global Animal Genetics Market 2020-2024 | COVID-19 Analysis, Drivers, Restraints, Opportunities and Threats | Technavio - Business...